摘要
目的探讨喹诺酮类抗生素联合前列舒通胶囊对慢性细菌性前列腺炎患者的疗效及对免疫炎症指标的影响。方法选取2020年3—6月在中一东北国际医院有限公司接受治疗的92例CBP患者作为研究对象,按随机数字表法分为观察组与对照组,各46例。对照组给予喹诺酮类药物治疗,观察组在对照组治疗基础上另服用前列舒通胶囊。比较两组疗效,治疗前及治疗2个月后的免疫指标(CD3+、CD4+、CD8+),以及炎症介质[超敏C-反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)及白细胞介素-6(IL-6)]。结果观察组治疗有效率是97.83,明显高于对照组的82.61%(P<0.05)。治疗后两组CD3+、CD4+及CD8+水平明显高于治疗前,且观察组明显高于对照组,差异有统计学意义(P<0.05)。治疗后,两组hs-CRP、TNF-α及IL-6水平明显低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。结论喹诺酮类抗生素联合前列舒通胶囊对CBP患者的疗效较好,还可优化机体的免疫炎症指标。
Objective To study the effect of quinolones combined with Qianlieshutong capsule on the immune inflammatory indexes of chronic bacterial prostatitis. Methods A total of 92 CBP patients admitted to Northeast International Hospitalwere selected from March 2020 to June 2020 were selected as the research objeccts and were divided into an observation group and a control group, with 46 cases in each group. Quinolones was given for the control group and observation group took another Qianlieshutong capsule plus Quinolones. Both groups were treated for 2 months. And then the efficacy, immunologic indicators before treatment and 2 months after treatment(CD3+、CD4+、CD8+), and inflammatory indicators(hs-CRP、TNF-α and IL-6) were compared. Results The total effective rate of the observation group was 97.83%, which was significantly higher than 82.61% of the control group(P<0.05). The CD3+、CD4+ and CD8+ levels of the 2 groups after treatment were significantly higher than those before treatment. And the observation group was also significantly higher than the control group(P<0.05). The hs-CRP、TNF-α and IL-6 levels of the 2 groups after treatment were significantly lower than those before treatment. And the observation group was also significantly lower than the control group(P<0.05). Conclusion Quinolones combined with Qianlieshutong Capsule is effective in CBP patients, It can also optimize the immune inflammation index of its body, It is worth popularizing in clinic.
作者
冯船洋
FENG Chuan-Yang(Department of Urology,Northeast International Hospital,Shenyang 110180,China)
出处
《中国药物经济学》
2021年第3期112-114,128,共4页
China Journal of Pharmaceutical Economics